Cat. No. BME100017



PRODUCT INFORMATION

Common Name SGN-35, cAC10-Val-Cit-MMAE **Synonyms** TNFRSF8;CD30;D1S166E;Ki-1

Applications ELISA; Flow Cyt

Recommended **Dilutions**

ELISA 1:5000-10000; Flow Cyt 1:100

Formulation & Reconstitution Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.

Host Species Chimeric IgG type lgG1

Reactivity Human **CD30 Target Uniprot ID** P28908

Description Anti-CD30 (brentuximab biosimilar) mAb

Delivery In Stock

> Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not

intended for use within a month, aliquot and store Storage & Shipping

at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient

temperature.

Research grade biosimilar. Not for use in

therapeutic or diagnostic procedures for humans **Background**

or animals.

Usage Research use only

Conjugate Unconjugated

> All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are

DIMA Disclaimer

actively scrutinizing all patent application to ensure no IP infringement.







Anti-CD30 (brentuximab biosimilar) mAb ELISA

0.2 µg of CD30, His Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 μ g/ml (100 μ L/well) Human CD30, His tagged protein (PME100481) can bind Anti-CD30 Neutralizing antibody in a linear range of 0.13-80.0 ng/ml.




Figure 2. Flow cytometry analysis with Anti-CD30 (brentuximab) on Expi293 cells transfected with human CD30 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).

Email: info@dimabio.com Website: www.dimabio.com








Figure 3. Flow cytometry analysis of antigen binding of anti-human CD30 mAb(BME100017). (A) A clear peak shift of BME100017 was seen compared to the control when incubated with CD30-expressing 8226 cells, indicating strong binding of BME100017 to CD30. Antibodies were incubated at 2 μ g/mL.



